Assessment of the In Vitro Kinetic Activity of Caspofungin against
            <i>Candida glabrata</i>

Nagappan, Viji; Boikov, Dina; Vázquez, José Antonio

doi:10.1128/aac.01339-08

Cited by 9 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, all three echinocandins exerted fungicidal activities against the susceptible isolate of C. glabrata. Our results are in agreement with those previously reported for caspofungin by Nagappan et al (19). These authors assessed the in vitro activity of caspofungin against fluconazole-susceptible and -resistant isolates and observed that the drug was fungicidal at concentrations of 1 g/ml and 4 g/ml.…”

Section: Discussionsupporting

confidence: 83%

Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata

Spreghini

Orlando²,

Sanguinetti

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The aim of this study was to compare the in vitro and in vivo activities of micafungin, caspofungin, and anidulafungin against Candida glabrata. The MICs against 28 clinical isolates showed that the overall susceptibilities to caspofungin and to micafungin were not statistically different in the absence of human serum, whereas the isolates were less susceptible to micafungin than to caspofungin in its presence. Minimum fungicidal concentrations, as well as time-kill experiments, showed that caspofungin was more active than anidulafungin, while micafungin was superior to either caspofungin or anidulafungin without serum; its addition rendered caspofungin and micafungin equally effective. A murine model of systemic candidiasis against a C. glabratasusceptible isolate was performed to study the effects of all three echinocandins, and kidney burden counts showed that caspofungin, micafungin, and anidulafungin were active starting from 0.25, 1, and 5 mg/kg of body weight/day, respectively. Two echinocandin-resistant strains of C. glabrata were selected: C. glabrata 30, a laboratory strain harboring the mutation Fks2p-P667T, and C. glabrata 51, a clinical isolate harboring the mutation Fks2p-D666G. Micafungin activity was shown to be as effective as or more effective than that of caspofungin or anidulafungin in terms of MICs. In vivo studies against these resistant strains showed that micafungin was active starting from 1 mg/kg/day, while caspofungin was effective only when administrated at higher doses of 5 or 10 mg/kg/day. Although a trend toward colony reduction was observed with the highest doses of anidulafungin, a significant statistical difference was never reached. Candida glabrata has recently been reported to be the second most common cause of invasive candidiasis, and there are increasing amounts of data showing its important role in determining either superficial or deep-seated infections (4, 18). Systemic infections due to C. glabrata are characterized by a high mortality rate, and they are difficult to treat due to reduced susceptibility of the species to azole drugs, especially to fluconazole (26). According to the published guidelines, amphotericin B can be used to treat infections due to C. glabrata, especially in profoundly immunocompromised hosts (22). Fortunately, the species also appears to be highly susceptible to the echinocandins (i.e., caspofungin, anidulafungin, and micafungin), making these agents valuable alternatives as first-line therapy against this Candida species (22). Interestingly, patients suffering from systemic candidiasis due to C. glabrata showed a trend, although not a significant one, to a better clinical outcome when treated with micafungin (87%) rather than with caspofungin (67%) (23).The three echinocandin antifungal agents anidulafungin, caspofungin, and micafungin have a unique mechanism of action, inhibiting ␤-1,3-D-glucan synthase, an enzyme that is necessary for the synthesis of ␤-1,3-D-glucan polymers, essential components of the cell walls of several fungi (8).Althou...

show abstract

Section: Discussionsupporting

confidence: 83%

Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata

Spreghini

Orlando²,

Sanguinetti

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

Arginolipid: A membrane‐active antifungal agent and its synergistic potential to combat drug resistance in clinical Candida isolates

Patil

Wanjare²,

Borse

et al. 2019

Archiv der Pharmazie

View full text Add to dashboard Cite

Antifungal drug resistance exhibits a major clinical challenge for treating nosocomial fungal infections. To find a possible solution, we synthesized and studied the antifungal activities of three different arginolipids (Nα‐acyl‐arginine ethyl ester) against clinical drug‐resistant isolates of Candida. The most active arginolipid, oleoyl arginine ethyl ester (OAEE) consisting of a long unsaturated hydrophobic chain, was tested for its mode of action, which revealed that it altered ergosterol biosynthesis and compromised the fungal cell membrane. Also, OAEE was found to exhibit synergistic interactions with fluconazole (FLU) or amphotericin B (AmB) against planktonic Candida cells, wherein it reduced the inhibitory concentrations of these drugs to their in vitro susceptible range. Studies conducted against the C. tropicalis biofilm revealed that the OAEE+AmB combination synergistically reduced the metabolic activity and hyphal density in biofilms, whereas OAEE+FLU was found to be additive against most cases. Finally, the evaluated selective toxicity of OAEE toward fungal cells over mammalian cells could establish it as an alternative treatment for combating drug‐resistant Candida infections.

show abstract

Candidemia por Candida glabrata en paciente joven sin enfermedad previa

González

Salanova

Orellana

et al. 2013

SEMERGEN - Medicina de Familia

View full text Add to dashboard Cite

Assessment of the In Vitro Kinetic Activity of Caspofungin against Candida glabrata

Cited by 9 publications

References 35 publications

Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata

Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata

Arginolipid: A membrane‐active antifungal agent and its synergistic potential to combat drug resistance in clinical Candida isolates

Candidemia por Candida glabrata en paciente joven sin enfermedad previa

Contact Info

Product

Resources

About